What USP General Chapter <800> governs

Some medications can harm workers through contact, inhalation or accidental transfer even when they are being used correctly for a patient. USP <800>, titled Hazardous Drugs—Handling in Healthcare Settings, provides controls for handling these drugs. Pharmacy technicians may encounter the chapter during receiving, storage, preparation, dispensing, transport, cleaning and waste handling.

Separate the hazardous-drug list from the handling standard

NIOSH publishes criteria and lists of hazardous drugs used in healthcare settings. USP <800> describes practice and quality standards for handling hazardous drugs; it does not itself serve as the list of every drug that is hazardous. Employers and compounding facilities use applicable NIOSH information, facility assessment and governing rules to determine which drugs require the hazardous-drug controls.

The handling path is broader than compounding

The USP scope includes receipt, storage, compounding, dispensing, administration and disposal of sterile and nonsterile hazardous drug products and preparations. Exposure can occur before a dose is prepared—for example, when a damaged package is received—and after it is administered, when packaging, contaminated materials or waste are handled. The facility's assessment should identify tasks and pathways that may expose personnel or the environment.

Controls protect people and the work area

Controls can include designated responsibilities, engineering controls, work practices, appropriate personal protective equipment, procedures for deactivation and decontamination, cleaning, spill response and documentation. The exact protection depends on the drug, dosage form, task and facility assessment. A technician should follow the site's hazardous-drug procedures, use required protective equipment and report spills, damaged packages or symptoms immediately.

What a technician should recognize

• Do not assume a final dosage form is harmless to handle; exposure risk depends on the task and the hazardous-drug assessment.
• Keep hazardous drugs segregated, identified and stored according to the facility's procedure.
• Use the required containment and PPE for the task; ordinary gloves may not provide the specified protection.
• Treat spills and contaminated waste under the designated response procedure.
• Ask the pharmacist or safety officer when the drug's status, handling steps or PPE is uncertain.
• USP <800> standards may be enforced through applicable state rules, accreditation requirements or facility policies; check the rules governing the practice site.

Avoid two common mix-ups

First, the NIOSH list and USP <800> serve different functions: one identifies hazardous drugs and the other gives handling standards. Second, hazardous-drug waste is not automatically classified the same way as RCRA hazardous waste. Occupational exposure controls and environmental waste rules can both apply, but each has its own definitions and requirements.

Key takeaway

USP <800> is about safely handling hazardous drugs across the healthcare workflow. Know which activities it covers, follow the site's drug assessment and controls, and keep occupational exposure questions separate from waste classification.

Scope follows the hazardous-drug list and task

USP <800> addresses safe handling of hazardous drugs in healthcare settings across receipt, storage, compounding, dispensing, administration, and disposal. NIOSH identifies hazardous drugs based on evidence of properties such as carcinogenicity, reproductive or developmental toxicity, organ toxicity at low doses, genotoxicity, or similar concern. Not every drug on a list creates the same exposure in every task, but a facility needs a documented assessment of risk and controls. The technician should follow the facility assessment and designated precautions rather than independently deciding a drug is harmless because it is a tablet.

Exposure pathways include inhalation of dust or droplets, skin contact with residue, ingestion from contaminated surfaces, and accidental sharps injury. Risk controls can include receiving procedures, storage segregation, engineering controls, work practices, appropriate PPE, cleaning and deactivation, and waste handling. A dosage form that is intact may present a different task risk from crushing, splitting, opening, or compounding it. Do not manipulate a hazardous dosage form unless the procedure authorizes the task and specifies controls.

Practical checks, exceptions, and exam application

A facility assessment should distinguish dosage form and manipulation. An intact tablet may be managed differently from a crushed tablet, opened capsule, or liquid spill because manipulation can increase exposure. Receiving and storage controls prevent damaged packages from contaminating other stock; compounding controls address higher exposure tasks; dispensing and administration controls prevent residue transfer; disposal protects staff and the environment. A technician should know where hazardous drugs are stored, what PPE applies, and how to obtain the current handling procedure.

Deactivation agents are not interchangeable, and some drug classes may not be adequately deactivated by commonly used bleach products. NIOSH and USP materials distinguish deactivation, decontamination, cleaning, and disinfection. Staff should not skip one step because another was completed. Use the sequence, contact time, and materials validated by the facility, and change PPE when required between contaminated and clean tasks.

Training is task-specific. A person trained only to receive intact packages may not be qualified to compound, clean a spill, or manage waste. Before performing an unfamiliar task, verify role authorization and training. If a package arrives damaged, do not carry it through the pharmacy as ordinary stock; isolate it and use the designated containment and reporting process.

Final workflow check

A risk assessment should be revisited when the hazardous-drug list, dosage form, equipment, or workflow changes. Do not rely on an old printed list if the facility directs staff to a current electronic version. When a product is not on the local handling list but a clinician requests manipulation, pause for review; absence from one shelf label does not authorize crushing or opening it. The safe response is to confirm classification and task-specific controls before exposure occurs.